BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.54 USD | -1.89% |
|
-6.76% | -19.04% |
| May. 23 | Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment | MT |
| May. 22 | Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million | RE |
Financials (USD)
| Sales 2024 * | 46.09B | Sales 2025 * | 46.06B | Capitalization | 85.83B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.41B | Net income 2025 * | 10.22B | EV / Sales 2024 * | 2.71 x |
| Net Debt 2024 * | 39.03B | Net Debt 2025 * | 31.68B | EV / Sales 2025 * | 2.55 x |
| P/E ratio 2024 * |
-16.1
x | P/E ratio 2025 * |
8.01
x | Employees | 34,100 |
| Yield 2024 * |
5.68% | Yield 2025 * |
5.97% | Free-Float | 69.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | -1.89% | ||
| 1 week | -6.76% | ||
| Current month | -5.46% | ||
| 1 month | -15.47% | ||
| 3 months | -19.07% | ||
| 6 months | -15.94% | ||
| Current year | -19.04% |
1 week
41.46
44.30
1 month
41.4649.05
Current year
41.4655.04
1 year
41.4666.69
3 years
41.4681.44
5 years
41.4681.44
10 years
41.4681.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 254 M€ | +12.80% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 17 M€ | +8.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 41.54 | -1.89% | 12,362,751 |
| 24-05-22 | 42.34 | +0.17% | 16,786,014 |
| 24-05-21 | 42.27 | -2.51% | 17,576,788 |
| 24-05-20 | 43.36 | -1.52% | 10,376,852 |
| 24-05-17 | 44.03 | -0.18% | 15,787,957 |
Delayed Quote Nyse, May 23, 2024 at 04:00 pm EDT
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-07-26
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.54
USD
Average target price
53.19
USD
Spread / Average Target
+28.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.04% | 85.83B | |
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
- Stock Market
- Equities
- BMY Stock
